Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 35HER2-positive Breast Cancer 3Brain Neoplasms 3Neoplasm Metastasis 2Endometrial Neoplasms 2Breast Diseases 2Anatomic Stage II Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Solid Cancer 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Motor Activity 1Metastatic Breast Cancer With a Isolated Brain Progression 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma 1Lung Neoplasms 1Invasive Breast Cancer 1Inflammatory Breast Neoplasms 1Hematologic Neoplasms 1

Interventions

pembrolizumab 3olaparib 2atezolizumab 2Trastuzumab 2zimberelimab 1tocilizumab 1spartalizumab 1pralsetinib 1pertuzumab 1ipatasertib 1inavolisib 1fludarabine 1entrectinib 1alectinib 1Radiotherapy 1Methotrexate 1Immune Checkpoint Inhibitors 1Docetaxel 1Cyclophosphamide 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Solid Tumors × pertuzumab × Clear all
NCT02320435 2026-05-12

A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

Hoffmann-La Roche

Phase 3 Active not recruiting
154 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡